101 related articles for article (PubMed ID: 12088341)
1. Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components.
Holten-Andersen MN; Brunner N; Christensen IJ; Jensen V; Nielsen HJ
Scand J Clin Lab Invest; 2002; 62(3):223-30. PubMed ID: 12088341
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor in blood transfusion components.
Riisbro R; Brünner N; Christensen IJ; Nielsen HJ
Transfus Med; 2004 Aug; 14(4):305-12. PubMed ID: 15285727
[TBL] [Abstract][Full Text] [Related]
3. Soluble vascular endothelial growth factor in various blood transfusion components.
Nielsen HJ; Werther K; Mynster T; Brünner N
Transfusion; 1999 Oct; 39(10):1078-83. PubMed ID: 10532601
[TBL] [Abstract][Full Text] [Related]
4. Cytokine generation in whole blood, leukocyte-depleted and temporarily warmed red blood cell concentrates.
Weisbach V; Wanke C; Zingsem J; Zimmermann R; Eckstein R
Vox Sang; 1999; 76(2):100-6. PubMed ID: 10085526
[TBL] [Abstract][Full Text] [Related]
5. Bacteria-induced release of white cell--and platelet-derived vascular endothelial growth factor in vitro.
Nielsen HJ; Werther K; Mynster T; Svendsen MN; Rosendahl S; Elley T; Skov F
Vox Sang; 2001 Apr; 80(3):170-8. PubMed ID: 11449957
[TBL] [Abstract][Full Text] [Related]
6. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates.
Edvardsen L; Taaning E; Dreier B; Christensen LD; Mynster T; Nielsen HJ
Am J Hematol; 2001 Jul; 67(3):157-62. PubMed ID: 11391711
[TBL] [Abstract][Full Text] [Related]
7. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations.
Lomholt AF; Frederiksen CB; Christensen IJ; Brünner N; Nielsen HJ
Clin Chim Acta; 2007 May; 380(1-2):128-32. PubMed ID: 17328880
[TBL] [Abstract][Full Text] [Related]
8. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study.
Holten-Andersen M; Christensen IJ; Nilbert M; Bendahl PO; Nielsen HJ; Brünner N; Fernebro E;
Eur J Cancer; 2004 Jan; 40(1):64-72. PubMed ID: 14687791
[TBL] [Abstract][Full Text] [Related]
9. Reduction of bioactive substances in stored donor blood: prestorage versus bedside leucofiltration.
Hammer JH; Mynster T; Reimert CM; Pedersen AN; Nielsen HJ
Eur J Haematol; 1999 Jul; 63(1):29-34. PubMed ID: 10414452
[TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation.
Fernández-Muñoz H; Plaza EM; Rivera-Caravaca JM; Candela MJ; Romera M; De Arriba F; Lozano ML; Vicente V; Heras I; Castilla-Llorente C; Rivera J
Hematology; 2018 Oct; 23(9):712-718. PubMed ID: 29582705
[TBL] [Abstract][Full Text] [Related]
11. Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay.
Holten-Andersen MN; Christensen IJ; Nielsen HJ; Lilja H; Murphy G; Jensen V; Brünner N; Piironen T
Clin Chem; 2002 Aug; 48(8):1305-13. PubMed ID: 12142388
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood.
Nielsen HJ; Reimert CM; Pedersen AN; Brünner N; Edvardsen L; Dybkjaer E; Kehlet H; Skov PS
Transfusion; 1996; 36(11-12):960-5. PubMed ID: 8937404
[TBL] [Abstract][Full Text] [Related]
13. Prestorage leukofiltration of whole blood and SAGM blood prevents extracellular bioactive substance accumulation.
Mynster T; Dybkjaer E; Reimert CM; Pedersen AN; Ostergaard K; Vangsgaard K; Nielsen HJ
Inflamm Res; 1999 Jul; 48(7):363-8. PubMed ID: 10450785
[TBL] [Abstract][Full Text] [Related]
14. A comparison of prestorage WBC-reduced whole-blood-derived platelets and bedside-filtered whole-blood-derived platelets in autologous progenitor cell transplant.
Sweeney JD; Kouttab NM; Penn CL; McHugh KE; Nelson EJ; Oblon DJ
Transfusion; 2000 Jul; 40(7):794-800. PubMed ID: 10924606
[TBL] [Abstract][Full Text] [Related]
15. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations.
Klüter H; Bubel S; Kirchner H; Wilhelm D
Transfusion; 1999; 39(11-12):1179-84. PubMed ID: 10604243
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a new whole-blood filter that allows preparation of platelet concentrates by platelet-rich plasma methods.
Lozano ML; Pérez-Ceballos E; Rivera J; Paunovic D; Candela MJ; Vicente V
Transfusion; 2003 Dec; 43(12):1723-8. PubMed ID: 14641870
[TBL] [Abstract][Full Text] [Related]
17. Cytokine generation in stored platelet concentrate: comparison of two methods of preparation.
Chaudhary R; Aggarwal A; Khetan D; Dayal R
Indian J Med Res; 2006 Oct; 124(4):427-30. PubMed ID: 17159263
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
19. Use of random versus apheresis platelet concentrates.
Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
[TBL] [Abstract][Full Text] [Related]
20. [Determination of the cytokine level during storage of partially leukocyte-depleted (<0.5 x 10(9)) or totally leukocyte-depleted (<0.5 x 10(6)) platelets].
Algora M; Barbolla L; Zamora C; Moreno C; Rodríguez MA; Merino JL; Torres P
Sangre (Barc); 1997 Jun; 42(3):159-64. PubMed ID: 9381255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
